Skip to main content
OpenTrials
Completed

NCT Number: NCT01726985

Model for Heart Failure ExAcerbation Reduction Trial

Heart failure is the leading cause of hospitalizations and readmissions in the United States and is a tremendous economic strain on our healthcare system. There is currently, based on national averages, a 30% readmission rate and 10% mortality rate within 3 months of being hospitalized for heart failure. Retrospective studies have shown benefit to using biomarkers such as BNP to guide inpatient heart failure management. Our own CCF retrospective study showed that decreasing NT-ProBNP by 23%, making patients fluid negative by more than 1.3L, and discharging patients with serum sodium above 135 reduces readmission rates significantly. The purpose of this study is to prospectively use the above mentioned goals in the treatment of heart failure in order to reduce heart failure readmission and mortality rates.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute on Chronic Heart Failure

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cleveland Clinic Florida

Weston, Florida, 33331, United States

About this study

All HF patients admitted to CCF will receive a short consent form. The study will enroll patients for one year. Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the 3 (above mentioned) criteria are met. Physicians will receive a copy of consent forms, educational bulletins, and discharge forms (as described in the Physician Education document which is attached to this application). Log-rank test will be used to compare groups. Chi-Square will be used to compare prospective patients with retrospective controls (obtained in 2010).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must have either Acute on Chronic Heart Failure or Chronic Heart Failure regardless of presenting/primary complaint

To fulfill CHF Dx, MUST have 2+ of the following:

  • Clinical: Dyspnea, orthopnea, PND, edema, S3, rales, improve w diuretics
  • Radiographic: Pulm venous congestion, pleural effs, cardiomegaly
  • Lab: NT pro BNP > 1000

Exclusion criteria

  • None

Treatment and study plan

Parameter Based Clinical Disposition

Other

Parameter Based Clinical Disposition'

Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:

  • NT-ProBNP reduction of > 23% from peak value during admission
  • Fluid Reduction of > 1.3L (orders for I/O q8h required)
  • Serum Sodium of > 135 mmol/L the day of planned discharge

Primary outcomes

  1. Hospital Readmission for CHF

    Time frame: up to 1 year

Secondary outcomes

  1. CHF Mortality

    Time frame: 90 days, 180 days, 1 yr

Sponsors and collaborators

Lead sponsor

Cleveland Clinic Florida

Other

Registry information

Official study title

Model for Heart Failure ExAcerbation Reduction Trial - "Model HEART"

Acronym: HEART

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Nov 15, 2012
Registry last updated
Apr 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.